CORT 118335

Drug Profile

CORT 118335

Alternative Names: CORT-118335

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Corcept Therapeutics
  • Class Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists; Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Metabolic disorders
  • Preclinical Non-alcoholic fatty liver disease

Most Recent Events

  • 08 May 2018 Corcept Therapeutics plans phase II trials in patients with Weight gain (antipsychotic-induced) and Non-alcoholic steatohepatitis by end of 2018
  • 15 Sep 2017 Phase-I clinical trials in Metabolic disorders (In volunteers) in United Kingdom (PO) (NCT03315338)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top